Founded in 2016 and with three assets in clinical trials, Cartesian is the leader in RNA cell therapy. Cartesian’s vision is to cure disease by RNA engineering any cell, to deliver to any tissue, any combination of therapies. The company is pioneering RNA cell therapies in and beyond oncology, with products in development for autoimmune, oncologic and respiratory disorders. All investigational therapies are manufactured at Cartesian’s wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Leadership Team:
Murat Kalayoglu, MD, PhD, President & CEO
Michael Singer, MD, PhD, Chief Scientific Officer
Metin Kurtoglu, MD, PhD, Chief Medical/Manufacturing Officer
The MSCRF facilitated a collaboration between Cartesian and leading researchers at the University of Maryland who conduct cutting edge research in respiratory disorders, in particular acute respiratory distress syndrome. This local collaboration, supported by MSCRF funds, paves the way for local sample collection and analysis following treatment with advanced cell therapy products, enabling new correlative studies that would not otherwise be possible if samples were to be collected/shipped overnight.